Request Demo
Last update 31 Aug 2025
99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)
Last update 31 Aug 2025
Overview
Basic Info
Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD44 inhibitors(CD44 antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
1
Clinical Trials associated with 99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)NCT02204033
A Phase I Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Head and Neck Cancer
100 Clinical Results associated with 99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)
Login to view more data
100 Translational Medicine associated with 99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)
Login to view more data
100 Patents (Medical) associated with 99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)
Login to view more data
100 Deals associated with 99mTc - labelled hMAb BIWA 4(Boehringer Ingelheim)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | 01 Mar 1999 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free